Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of August 2017, specifically dated August 23, 2017. The filing reports a strategic commercial milestone involving the Company's lead product candidate, Namodenoson (CF102), for the treatment of liver cancer.
Key Financial Metrics
The filing discloses a specific cash inflow event but does not provide comprehensive financial statements for the period.
- Revenue/Cash Inflow: The Company received a milestone payment of $500,000.
- Counterparty: Payment received from Chong Kun Dang Pharmaceuticals (CKD).
- Other Metrics: The filing text does not provide clear values for net profit, operating cash flow, margins, total debt, or overall liquidity positions.
Material Changes
The primary material change reported is the execution of a payment obligation under a licensing agreement. CKD paid the $500,000 milestone upon the Company securing the exclusive right to distribute Namodenoson in Korea, contingent upon receipt of regulatory approvals. No other material changes to financial position or operations are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" from the attached press release (Exhibit 99.1) but does not explicitly restate specific numerical guidance or detailed risk factors within the body of this Form 6-K. The transaction highlights the Company's reliance on regulatory approvals in Korea to fully realize the commercial potential of the distribution agreement.
Investor Verification Checklist
- Verify the status of regulatory approvals for Namodenoson in Korea to confirm the conditions for future payments or commercialization.
- Review the full text of the attached press release (Exhibit 99.1) for detailed forward-looking statements and risk disclosures.
- Check subsequent filings for the impact of this $500,000 milestone on the Company's overall cash position and burn rate.
- Confirm the terms of the exclusive distribution agreement with Chong Kun Dang Pharmaceuticals regarding future milestones.